The value of the MDR 1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia ( AML ) , in relation to MDR 1 status at diagnosis

No abstract is available for this paper.

• Publication year

  year unknown

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• International System for Human Cytogenetic Nomenclature

  2020cited by this paper
• Nonparametrics Statistical Methods Based On Ranks

  2016cited by this paper
• St. Joseph's Health Centre

  2010cited by this paper
• Applied Logistic Regression: Hosmer/Applied Logistic Regression

  2005cited by this paper
• Acute myeloid leukemia

  2004cited by this paper
• Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Group B Study 9621.

  2004cited by this paper
• P-glycoprotein (Pgp) modulation in untreated acute myeloid leukemia (AML): Cancer and Leukemia Group B (CALGB) trials in younger and older adults.

  2004cited by this paper
• Addition of cyclosporin A to the combination of mitoxantrone and etoposide to overcome resistance to chemotherapy in refractory or relapsing acute myeloid leukaemia: a randomised phase II trial from HOVON, the Dutch-Belgian Haemato-Oncology Working Group for adults.

  2004cited by this paper
• Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995).

  2004cited by this paper
• Immunophenotyping as a guide for targeted therapy.

  2003cited by this paper
• A phase I/II study of the MDR modulator Valspodar (PSC 833) combined with daunorubicin and cytarabine in patients with relapsed and primary refractory acute myeloid leukemia.

  2003cited by this paper
• Categorical Data Analysis

  2003cited by this paper
• Attempts to modulate chemoresistance in older patients with AML using PSC-833 - Results of the LRF AML14 trial

  2003cited by this paper
• Quinine as a multidrug resistance inhibitor: a phase 3 multicentric randomized study in adult de novo acute myelogenous leukemia.

  2003cited by this paper
• Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720.

  2002cited by this paper
• Combined action of PSC 833 (Valspodar), a novel MDR reversing agent, with mitoxantrone, etoposide and cytarabine in poor-prognosis acute myeloid leukemia

  2001cited by this paper
• Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial.

  2001cited by this paper
• Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study.

  2001cited by this paper
• Comparison of ‘sequential’ versus ‘standard’ chemotherapy as re‐induction treatment, with or without cyclosporine, in refractory/relapsed acute myeloid leukaemia (AML): results of the UK Medical Research Council AML‐R trial

  2001cited by this paper
• Phase I/II study of the P-glycoprotein modulator PSC 833 in patients with acute myeloid leukemia.

  2001cited by this paper
• Chemotherapy resistance in acute myeloid leukaemia.

  2001cited by this paper
• Clinical significance of P-glycoprotein expression and function for response to induction chemotherapy, relapse rate and overall survival in acute leukemia.

  2000cited by this paper
• P-glycoprotein and multidrug resistance protein activities in relation to treatment outcome in acute myeloid leukemia.

  2000cited by this paper
• P-Glycoprotein inhibitor valspodar (PSC 833) increases the intracellular concentrations of daunorubicin in vivo in patients with P-glycoprotein-positive acute myeloid leukemia.

  2000cited by this paper
• A phase I study of induction chemotherapy for older patients with newly diagnosed acute myeloid leukemia (AML) using mitoxantrone, etoposide, and the MDR modulator PSC 833: a southwest oncology group study 9617.

  2000cited by this paper
• Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (Valspodar).

  1999cited by this paper
• Treatment of Refractory and Relapsed Acute Myelogenous Leukemia With Combination Chemotherapy Plus the Multidrug Resistance Modulator PSC 833 (Valspodar)

  1999cited by this paper
• Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study.

  1999cited by this paper
• An inventory of the human ABC proteins.

  1999cited by this paper
• A Placebo-Controlled Study of Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor Administered During and After Induction Treatment for De Novo Acute Myelogenous Leukemia in Elderly Patients

  1998cited by this paper
• A placebo-controlled study of recombinant human granulocyte-macrophage colony-stimulating factor administered during and after induction treatment for de novo acute myelogenous leukemia in elderly patients. Groupe Ouest Est Leucémies Aiguës Myéloblastiques (GOELAM).

  1998cited by this paper
• A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest oncology group study (9031).

  1998cited by this paper
• Phase I study of mitoxantrone plus etoposide with multidrug blockade by SDZ PSC-833 in relapsed or refractory acute myelogenous leukemia.

  1997cited by this paper
• MDR 1 expression is an independent prognostic factor for response and survival in de novo acute myeloid leukaemia

  1997cited by this paper
• Non-P-glycoprotein drug export mechanisms of multidrug resistance.

  1997cited by this paper
• Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study.

  1997cited by this paper
• Pharmacologic approaches to reversing multidrug resistance.

  1997cited by this paper
• Combination of quinine as a potential reversing agent with mitoxantrone and cytarabine for the treatment of acute leukemias: a randomized multicenter study.

  1996cited by this paper
• Quality control of multidrug resistance assays in adult acute leukemia: correlation between assays for P-glycoprotein expression and activity.

  1996cited by this paper
• Cytogenetics and P-glycoprotein (PGP) are independent predictors of treatment outcome in acute myeloid leukemia (AML).

  1996cited by this paper
• Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B.

  1995cited by this paper
• Predominance of functional multidrug resistance (MDR-1) phenotype in CD34+ acute myeloid leukemia cells.

  1993cited by this paper
• Enhancement of daunorubicin accumulation, retention, and cytotoxicity by verapamil or cyclosporin A in blast cells from patients with previously untreated acute myeloid leukemia.

  1993cited by this paper
• Clinical significance of P-glycoprotein in multidrug resistance malignancies.

  1993cited by this paper
• Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis.

  1992cited by this paper
• Efficient inhibition of P-glycoprotein-mediated multidrug resistance with a monoclonal antibody.

  1992cited by this paper
• Reversal of typical multidrug resistance by cyclosporin and its non-immunosuppressive analogue SDZ PSC 833 in Chinese hamster ovary cells expressing themdr1 phenotype

  1992cited by this paper
• Detection of activity of P‐glycoprotein in human tumour samples using rhodamine 123

  1992cited by this paper
• SDZ PSC 833, a non-immunosuppressive cyclosporin analog, is a very potent multidrug-resistance modifier

  1991cited by this paper
• Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells.

  1991cited by this paper
• MDR1 gene expression and treatment outcome in acute myeloid leukemia.

  1991cited by this paper
• Overexpression of the MDRL gene in blast cells from patients with acute myelocytic leukemia is associated with decreased anthracycline accumulation that can be restored by cyclosporin‐A

  1990cited by this paper
• Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia.

  1990cited by this paper
• Blood.

  1989cited by this paper
• The multidrug transporter, a double-edged sword.

  1988influential reference
• Tissue distribution of P-glycoprotein encoded by a multidrug-resistant gene as revealed by a monoclonal antibody, MRK 16.

  1988cited by this paper
• Multiple-drug resistance in human cancer.

  1987influential reference
• Isolation of human mdr DNA sequences amplified in multidrug-resistant KB carcinoma cells.

  1986cited by this paper
• Characterization of a new drug-resistant human myeloma cell line that expresses P-glycoprotein.

  1986cited by this paper
• Evaluation of survival data and two new rank order statistics arising in its consideration.

  1966cited by this paper
• Nonparametric Estimation from Incomplete Observations

  1958cited by this paper
• Regression Models and Life-Tables

  year unknowncited by this paper

• Mechanisms of drug resistance in colon cancer and its therapeutic strategies.

  2016cites this paper
• Ponatinib enhances anticancer drug sensitivity in MRP7-overexpressing cells

  2014cites this paper
• Nanodiamond–Mitoxantrone Complexes Enhance Drug Retention in Chemoresistant Breast Cancer Cells

  2014cites this paper
• The Pim kinase inhibitor SGI-1776 decreases cell surface expression of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and drug transport by Pim-1-dependent and -independent mechanisms.

  2013cites this paper
• Cianfriglia Targeting MDR 1P-glycoprotein ( MDR 1-Pgp ) in immunochemotherapy of acute myeloid leukemia ( AML )

  2013cites this paper
• Primed for the kill: occupying Bcl-2 to target death in acute myeloid leukaemia

  2012cites this paper
• Administration schedule of daunorubicin for elderly patients with acute myelogenous leukemia: a single-institute experience.

  2011cites this paper
• The Feasibility of Inpatient Geriatric Assessment for Older Adults Receiving Induction Chemotherapy for Acute Myelogenous Leukemia

  2011cites this paper
• Sequential phase II Southwest Oncology Group studies (S0112 and S0301) of daunorubicin and cytarabine by continuous infusion, without and with ciclosporin, in older patients with previously untreated acute myeloid leukaemia

  2010cites this paper
• Has there been progress in the treatment of older patients with acute myeloid leukemia?

  2010cites this paper
• The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial

  2009cites this paper
• Identification of genes that confer tumor cell resistance to the Aurora B kinase inhibitor, AZD1152

  2009cites this paper
• High-dose daunorubicin in older patients with acute myeloid leukemia.

  2009cites this paper
• Rapid induction of P-glycoprotein mRNA and protein expression by cytarabine in HL-60 cells.

  2009cites this paper
• An overview of cancer multidrug resistance: a still unsolved problem

  2008cites this paper
• Alleviation of the drug-resistant phenotype in idarubicin and cytosine arabinoside double-resistant acute myeloid leukemia cells by indomethacin.

  2008cites this paper
• MDR1 polymorphism influences the outcome of multiple myeloma patients

  2007cites this paper
• Prognostic factors in elderly patients with AML and the implications for treatment.

  2007cites this paper
• Case–control study of multidrug resistance phenotype and response to induction treatment including or not fludarabine in newly diagnosed acute myeloid leukaemia patients

  2007influential citation
• Gemtuzumab ozogamicin in combination with attenuated doses of standard induction chemotherapy can successfully induce complete remission without increasing toxicity in patients with acute myeloid leukemia aged 55 or older

  2007cites this paper
• ABCB1 gene polymorphisms are not associated with treatment outcome in elderly acute myeloid leukemia patients

  2006cites this paper
• FARMACOGENÉTICA APLICADA AO CÂNCER. QUIMIOTERA- PIA INDIVIDUALIZADA E ESPECIFICIDADE MOLECULAR

  2006cites this paper
• Non-transplant therapy for older adults with acute myeloid leukemia.

  2006cites this paper
• Novel Agents in Acute Myeloid Leukemia

  2006cites this paper
• Targeting multidrug resistance in cancer

  2006cites this paper
• Response : Is there any evidence supporting a critical role of ectopic PI-9 expression in tumor immune escape ?

  2006cites this paper
• Current therapeutic strategies for acute myeloid leukaemia

  2006cites this paper